Showing 8981-8990 of 19239 results for "".
- ‘Symptom Triggered’ Test Can Pick Up Early-Stage Aggressive Ovarian Cancer in 1 in 4 of Affectedhttps://reachmd.com/news/symptom-triggered-test-can-pick-up-early-stage-aggressive-ovarian-cancer-in-1-in-4-of-affected/2467803/Symptom triggered testing, prompted by symptoms such as pain, abdominal bloating/swelling, and feeling full soon after starting to eat, can pick up early-stage aggressive ovarian cancer in 1 in 4 of those affected, according to new research. A study published in the I
- Disparities in Post-Stroke Care Detailed in New Studyhttps://reachmd.com/news/disparities-in-post-stroke-care-detailed-in-new-study/2467448/Hispanic people and people without private insurance who have experienced a stroke are more likely to be discharged to their home rather than to a health care facility, according to data published in Neurology Clinical Practice. The report provided additional insights i
- EHA 2024: Monoclonal Antibodies Continue to Dominate Multiple Myeloma Treatments - Pharmaceutical Technologyhttps://reachmd.com/news/eha-2024-monoclonal-antibodies-continue-to-dominate-multiple-myeloma-treatments-pharmaceutical-technology/2467321/Many significant Phase I-III studies targeting haematological malignancies, such as multiple myeloma (MM), were presented at the European Hematology Association Hybrid Congress 2024 (EHA 2024), which took place from 13 – 16 June. MM is the third
- EHA 2024: Monoclonal Antibodies Continue to Dominate Multiple Myeloma Treatmentshttps://reachmd.com/news/eha-2024-monoclonal-antibodies-continue-to-dominate-multiple-myeloma-treatments/2467248/Many significant Phase I-III studies targeting haematological malignancies, such as multiple myeloma (MM), were presented at the European Hematology Association Hybrid Congress 2024 (EHA 2024), which took place from 13 – 16 June. MM is the third most prevalent blood cancer w
- Dermavant Publishes ADORING 1 & ADORING 2 Phase 3 Trial Results for Vtama Cream for ADhttps://reachmd.com/news/dermavant-publishes-adoring-1-adoring-2-phase-3-trial-results-vtama-cream-ad/2463173/Dermavant Sciences announced that the data from ADORING 1 and ADORING 2 phase 3 trials of Vtama (tapinarof) cream 1% for adults and children 2 years of age and older with atopic dermatitis (AD) has been published in the Journal of the American Academy of Dermatology. Vtama cream i
- COVID-19 Vaccine Can Help People with Heart Failure Live Longerhttps://reachmd.com/news/covid-19-vaccine-can-help-people-with-heart-failure-live-longer/2463034/Heart failure patients who are vaccinated against COVID-19 have an 82% greater likelihood of living longer than those who are not vaccinated, according to research presented today at Heart Failure 2024, a scientific congress of the European Society of Cardiology (ESC).1 Heart Failure i
- Common Environmental Carcinogens Reduce Lifespan Joyhttps://reachmd.com/news/common-environmental-carcinogens-reduce-lifespan-joy/2462550/Osaka, Japan – If improving your outlook on life really was as simple as "don't worry, be happy," then keeping your spirits up would be a piece of cake. Unfortunately, it's not so simple, as a multitude of factors beyond our control can affect our mood.In a study published i
- Akouos Reports Positive Data from Gene Therapy Trial for Hearing Losshttps://reachmd.com/news/akouos-reports-positive-data-from-gene-therapy-trial-for-hearing-loss/2456956/Elil Lilly and Company subsidiary Akouos has reported encouraging initial data from the Phase I/II AK-OTOF-101 clinical trial of its investigational gene therapy, AK-OTOF, for genetic hearing loss. The trial has demonstrated pharmacologic hearing restoration within 30 days of administrati
- Vaccine Demonstrates Benefit in Delaying Cancer Relapsehttps://reachmd.com/news/vaccine-demonstrates-benefit-in-delaying-cancer-relapse/2456841/Vaccine demonstrates benefit in delaying cancer relapseData from the Phase I trial showed that the cancer vaccine offered an 86 percent reduction in the risk of relapse or death in pancreatic and colorectal cancers.A lymph node-targeted cancer vaccine has
- Dual Biologic Therapy Promotes Hair Follicle Regeneration in Preclinical Studyhttps://reachmd.com/news/dual-biologic-therapy-promotes-hair-follicle-regeneration-in-preclinical-study/2485066/New preclinical research suggests that combining botulinum neurotoxin type A (BoNT/A) with platelet-rich plasma (PRP) may synergistically promote hair follicle regeneration through activation of the Wnt/β-catenin signaling pathway and modulation of stathmin 1 (STMN1) protein expression. The findi